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Hypoxia-inducible factor-1a (HIF-1a) is a transcription factor
that mediates many cellular responses to tissue hypoxia, a
common feature of acute kidney injury (AKI). Here we studied
241 patients with AKI and determined the relationship to
adverse outcome of a non-synonymous polymorphism in the
coding region of the HIF-1a gene where a C to T substitution
occurs at position þ 85 in exon 12, a change known to
enhance transactivation. The baseline characteristics of the
patients were not different among genotype groups except
for a significantly higher prevalence of shock and number of
failed organs in T-allele carriers. A significant
genotype–phenotype association was found for plasma levels
of vascular endothelial growth factor-A but not angiopoietin-
2, two downstream targets of HIF-1a. Compared to the CC
genotype, T-allele carriers had significantly higher adjusted
odds for dialysis requirement or in-hospital death; assisted
mechanical ventilation or dialysis requirement; and the
composite of assisted mechanical ventilation, dialysis
requirement or in-hospital death. The trend for higher
plasma angiopoietin-2 levels was associated with
significantly higher adjusted odds for in-hospital death;
dialysis requirement or in-hospital death; and the composite
outcome of assisted mechanical ventilation, dialysis, or
in-hospital death. Despite the limited cohort size, our study
found this particular HIF-1a genetic variant to be associated
with disease severity and adverse outcomes in AKI. Larger
studies are needed to confirm these relationships.
Kidney International (2009) 75, 1322–1329; doi:10.1038/ki.2009.68;
published online 11 March 2009
KEYWORDS: acute kidney injury; angiopoietin-2; gene polymorphism;
HIF-1a; VEGF-A
Acute kidney injury (AKI), as defined by a wide range of
serum creatinine increments, is a consistent and powerful
predictor of in-hospital mortality, and is associated with an
increase in length of stay at hospital, hospital costs, and post-
hospitalization resource utilization.1,2 The limited oxygen
supply to renal tissue renders the kidney susceptible to
hypoxia, particularly the medulla, and has been long
recognized as an important factor in the pathogenesis of
AKI.3 Hypoxia-inducible factor-1a (HIF-1a) is the major
transcription factor that mediates cellular responses to tissue
hypoxia. Similar to other organs, ischemia-reperfusion injury
in the kidney evokes activation of several hypoxia-inducible
genes by HIF-1a,3 and may play an important role in the
development, propagation, and resolution of AKI.
In recent years, polymorphisms of host-response candidate
genes have emerged as potentially important determinants of
disease severity and adverse outcomes in AKI.4,5 A non-
synonymous polymorphism in the coding region of the HIF-
1a gene (exon 12, position þ 85, C to T single-nucleotide
substitution; RefSNP no. rs11549465) resulting in proline to
serine substitution (codon 1, position 582) has recently been
described and shown to increase the transactivation potential of
the transcription factor.6 In this study, using a candidate-gene
approach, we examined the association of this HIF-1a genetic
variant with measures of disease severity and adverse outcomes
in a cohort of hospitalized patients with established AKI,
focusing mainly on dialysis requirement, assisted mechanical
ventilation, and in-hospital mortality. We also explored the
association of this polymorphism with two intermediate
phenotypes, plasma levels of vascular endothelial growth factor-
A (VEGF-A) and angiopoietin-2 (Ang-2), pro- and antiangio-
genic factors, respectively, under the control of HIF-1a. Because
these factors have previously been linked to adverse outcomes in
critically ill patients,7,8 we probed their potential impact in AKI.
RESULTS
Characteristics of the cohort stratified by HIF-1a genotypes
Hypoxia-inducible factor-1a genotyping was performed on
241 consecutive study participants. The minor allele
frequency of the HIF-1a exonic þ 85 T-allele was 14%.
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Testing for Hardy–Weinberg equilibrium did not detect
deviation from expected frequencies (P¼ 0.88). Table 1 displays
the baseline characteristics of the cohort according to the
different HIF-1a genotypes. In brief, no significant age, sex, and
race differences were observed among the different genotype
groups. The remaining characteristics did not differ significantly
among the genotype groups, except for a higher prevalence of
shock (Table 1) and a higher number of failed organs, as defined
by the multiple organ failure (MOF) score, in carriers of the CT
and TT genotypes (Figure 1, P¼ 0.04). The HIF-1a T-allele was
associated with a higher MOF score category (odds ratio 1.94;
95% confidence interval (CI) 1.05, 3.57; P¼ 0.03).
Association of HIF-1a genotypes with plasma VEGF-A and
Ang-2 levels
A genotype–phenotype association was demonstrable
between the HIF-1a genotypes and plasma VEGF-A levels
(P¼ 0.02 for trend). Patients with the HIF-1a CT genotype
had higher plasma VEGF-A levels as compared with those
with the CC genotype (Figure 2a; P¼ 0.006). When the CT
and TT genotypes were combined (there were only five
carriers of the TT genotype in our cohort), the T-allele
carriers had markedly higher plasma VEGF-A levels as
compared with carriers of the CC genotype (54±7 vs
34±4 pg/ml; P¼ 0.008). There was no significant association
between plasma Ang-2 levels and HIF-1a genotypes (P¼ 0.24),
although a trend toward higher values appeared among the five
carriers of the TT genotype (Figure 2b). Similarly, when we
combined the CT and TT genotypes, the T-allele carriers had
higher plasma Ang-2 levels as compared to those with the CC
genotype, but this did not reach statistical significance
(18 335±2610 vs 15 305±1517 pg/ml; P¼ 0.32).
Association of HIF-1a genotypes with adverse clinical
outcomes
As shown in Table 2, carriers of the HIF-1a CT/TT genotype
had a higher requirement for dialysis (P¼ 0.03) or assisted
Table 1 | Characteristics of patients with AKI stratified by
HIF-1a exon 12 (+85) genotypes
HIF-1a exon 12 (+85) genotypes
Characteristic CC (N=180) CT (N=56) TT (N=5) P-value
Age (years) 64 (16) 67 (16) 74 (14) 0.15
Male sex (%) 54 48 40 0.61
Race (%) 0.62
White 90 91 100
Black 7 4 0
Other 3 5 0
Contributing cause of AKI (%) 0.54
Ischemic 28 20 60
Nephrotoxic 16 21 0
Septic 9 11 0
Multifactorial/other 47 48 40
Coexisting conditions (%)
Diabetes mellitus 42 48 60 0.52
Heart failure 14 18 0 0.53
Cirrhosis 8 7 0 0.93
Chronic lung disease 19 16 20 0.88
Chronic kidney disease 32 38 20 0.61
ICU setting (%) 74 75 80 0.96
APACHE II score 20 (6) 20 (7) 21 (8) 0.78
Sepsis (%) 43 48 60 0.60
Shock (%) 24 41 60 0.01
Serum creatinine (mg per 100 ml)
Baseline value 1.6 (0.6) 1.5 (0.6) 1.4 (0.7) 0.75
Enrollment value 3.7 (2.0) 3.6 (1.9) 2.4 (0.5) 0.33
Oliguria (%) 23 16 20 0.61
AKI, acute kidney injury; HIF-1a, hypoxia-inducible factor-1a.
The values are expressed as means (and s.d.) or percentages.
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Figure 1 | Multiple organ failure (MOF) score stratified by HIF-
1a genotypes. P¼ 0.04 by w2-test.
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Figure 2 | (a) Plasma vascular endothelial growth factor-A (VEGF-
A) and (b) plasma angiopoietin (Ang-2) level stratified by HIF-1a
genotypes. The data are presented as mean (s.e.) values that are
adjusted for the white blood cell and platelet counts. *P¼ 0.006
vs CC genotype.
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mechanical ventilation (P¼ 0.05), as well as higher compo-
site end points of dialysis requirement or in-hospital death
(P¼ 0.001), assisted mechanical ventilation or dialysis
requirement (P¼ 0.005), and assisted mechanical ventilation,
dialysis requirement, or in-hospital death (P¼ 0.001).
Results of the logistic regression analyses are displayed in
Table 3. In the unadjusted analyses, compared with the CC
genotype, the HIF-1a T-allele carrier state was associated
with 2.89-fold higher odds for dialysis requirement or
in-hospital death, 2.58-fold higher odds for assisted mechan-
ical ventilation or dialysis requirement, and 3.28-fold
higher odds for assisted mechanical ventilation, dialysis
requirement, or in-hospital death. These associations
persisted with 3.61-, 3.39-, and 4.74-fold higher odds for
these respective composite end points after adjustment
for sex, race, and APACHE II score. Similar associations
were observed after adjustment for sex, race, APACHE II
score, and shock (Table 3), as well as after adjustment for sex,
race, and age, and either the MOF score or sepsis (data not
shown).
Using the additive models, each copy of the HIF-1a
T-allele was independently associated with 2.90-fold higher
odds for dialysis requirement or in-hospital death (95% CI
1.52, 5.56), 3.08-fold higher odds for assisted mechanical
ventilation or dialysis requirement (95% CI 1.55, 6.16), and
4.05-fold higher odds for assisted mechanical ventilation,
dialysis requirement or in-hospital death (95% CI 1.96, 8.41),
after adjustment for sex, race, and APACHE II score. The
addition of shock to these models did not affect any of these
point estimates (data not shown).
Association of plasma VEGF-A or Ang-2 levels with adverse
clinical outcomes
We constructed a restrictive cubic spline to ascertain the
crude relationship between plasma VEGF-A or Ang-2 and
dialysis requirement or in-hospital death (Figure 3). Increas-
ing plasma levels of VEGF-A were not associated with this
composite outcome (P¼ 0.39; Figure 3a). By contrast,
increasing plasma levels of Ang-2 were associated with a
progressively higher probability of dialysis requirement or in-
hospital death (Po0.0001; Figure 3b).
Plasma VEGF-A (odds ratio 0.95; 95% CI 0.91, 0.99;
P¼ 0.03) and plasma Ang-2 (odds ratio 3.83; 95% CI 2.55,
5.75; Po0.0001) were also associated with the MOF score,
but these associations were in opposite directions.
Results of the logistic regression analyses are displayed in
Table 4. In the unadjusted analyses, plasma VEGF-A level was
associated with 0.90-fold lower odds for in-hospital death,
which persisted after adjustment for sex, race, APACHE II
score, and HIF-1a genotypes. However, there was no
association between this proangiogenic factor and the
composite end points (Table 4). In the unadjusted analyses,
plasma Ang-2 level was associated with 3.28-fold higher odds
for in-hospital death, 2.34-fold higher odds for dialysis
requirement or in-hospital death, 2.12-fold higher odds
for assisted mechanical ventilation or dialysis requirement,
and 2.27-fold higher odds for the composite of assisted
Table 2 | Outcomes of patients with AKI stratified by HIF-1a exon 12 (+85) genotypes
HIF-1a exon 12 (+85) genotypes
Characteristic CC (N=180) CT (N=56) TT (N=5) P-value
Requirement for assisted mechanical ventilation (%) 22 32 60 0.05
Persistent mechanical ventilation at hospital discharge (%) 14 23 40 0.09
Dialysis requirement (%) 37 55 60 0.03
In-hospital death (%) 22 32 20 0.27
Dialysis requirement or in-hospital death (%) 43 70 60 0.002
Assisted mechanical ventilation or dialysis requirement (%) 46 68 80 0.008
Assisted mechanical ventilation, dialysis requirement, or in-hospital death (%) 48 75 80 0.001
AKI, acute kidney injury; HIF-1a, hypoxia-inducible factor-1a.
The values are expressed as means (and standard deviations) or percentages.
Table 3 | Association of HIF-1a exon 12 (+85) genotypes with
adverse clinical outcomes in patients with AKI
HIF-1a CT/TT genotypes
(vs CC genotype) OR 95% CI P-value
In-hospital death
Unadjusted 1.64 0.86, 3.13 0.14
Adjusted for race, sex, and
APACHE II score
1.53 0.72, 3.29 0.27
Adjusted for race, sex, APACHE II
score, and shock
1.49 0.69, 3.24 0.31
Dialysis requirement or in-hospital death
Unadjusted 2.89 1.56, 5.36 o0.001
Adjusted for race, sex, and
APACHE II score
3.61 1.77, 7.39 o0.001
Adjusted for race, sex, APACHE II
score, and shock
3.87 1.87, 8.01 o0.001
Assisted mechanical ventilation or dialysis requirement
Unadjusted 2.58 1.39, 4.78 0.003
Adjusted for race, gender, and
APACHE II score
3.39 1.60, 7.19 0.001
Adjusted for race, sex, APACHE II
score, and shock
3.67 1.70, 7.89 0.001
Assisted mechanical ventilation, dialysis requirement, or in-hospital death
Unadjusted 3.28 1.71, 6.29 0.0004
Adjusted for race, gender, and
APACHE II score
4.74 2.16, 10.43 0.0001
Adjusted for race, sex, APACHE II
score, and shock
4.73 2.14, 10.47 0.0001
AKI, acute kidney injury; 95% CI, 95% confidence interval for the odds ratio (OR);
HIF-1a, hypoxia-inducible factor-1a.
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mechanical ventilation, dialysis requirement, or in-hospital
death. These associations persisted for in-hospital death, and
for all three composite end points after adjustment for sex,
race, APACHE II score, and HIF-1a genotypes (Table 4). Of
note, the HIF-1a T-allele was independently associated with
3.57-fold higher odds for dialysis requirement or in-hospital
death (95% CI 1.73, 7.35), 3.37-fold higher odds for assisted
mechanical ventilation or dialysis requirement (95% CI 1.59,
7.15), and 4.69-fold higher odds for assisted mechanical
ventilation, dialysis requirement or in-hospital death (95%
CI 2.13, 10.33), after adjustment for sex, race, APACHE II
score, and Ang-2 level. There was no interaction between
HIF-1a genotypes and either plasma VEGF-A or Ang-2 for
the various end points (data not shown).
DISCUSSION
This study evaluates the relationship of a functional genetic
variant in the coding region of the HIF-1a gene to adverse
clinical outcomes in a large cohort of hospitalized patients
with established AKI of mixed etiology and severity. The
observed and expected genotype frequencies were not
significantly different, thereby fulfilling the Hardy–Weinberg
equilibrium, and there were no race, gender, or age
differences within genotype groups. The HIF-1a genotypes
influenced plasma levels of VEGF-A but not Ang-2, two HIF-
1a-regulated gene products. After adjustment for sex, race,
and APACHE II score, the HIF-1a T-allele carriers (CT and
TT genotypes) had a higher prevalence of shock and multiple
organ failure, and higher odds for the composite end points
of dialysis requirement or in-hospital death, assisted
mechanical ventilation or dialysis requirement, and assisted
mechanical ventilation, dialysis requirement, or in-hospital
death. Although plasma VEGF-A levels were significantly
higher among carriers of the HIF-1a T-allele, higher levels of
this proangiogenic factor were associated with lower odds for
in-hospital death. By contrast, although there was a
nonsignificant trend toward higher plasma Ang-2 levels
among the HIF-1a T-allele carriers, higher levels of this
antiangiogenic factor were associated with higher odds for
in-hospital death and the three afore-mentioned composite
end points.
The limitation in oxygen supply to renal tissue renders the
kidney susceptible to hypoxia and has been long recognized
as an important factor in the pathogenesis of AKI.3 HIF-1a is
a transcription factor that mediates cellular responses to
tissue hypoxia.9 By forming a heterodimeric complex with
the b-unit (HIF-1b) on hypoxic responsive elements, HIF-1a
activates transcription of a wide array of genes as a part of the
cellular response to hypoxia. HIF-1b is ubiquitously ex-
pressed and maintained at constant cellular levels, whereas
HIF-1a protein levels and transcriptional activity are tightly
regulated in response to oxygen levels. Under normoxic
conditions, HIF-1a is hydroxylated on proline residues by
oxygen-dependent prolyl hydroxylases, which mediate ubi-
quitination and degradation of HIF-1a. The critical proline
residues that mediate binding when hydroxylated are at
position P402 and P564, both located in the oxygen-
dependent domain.
Given its importance in mediating cellular repsonses to
hypoxia, one might anticipate that polymorphisms disrupt-
ing the function of HIF-1a would alter tissue responses in
conditions such as AKI. Several polymorphisms in the gene
encoding HIF-1a have been described. Among them, the
non-synonymous polymorphism in the coding region of the
HIF-1a gene (exon 12, position þ 85, C to T single-
nucleotide substitution) results in proline to threonine
substitution (codon 1, position 582).6,10 This mutation at
P582 renders HIF-1a less sensitive to hydroxylation-depen-
dent degradation, thereby increasing the transactivation
potential of this transcription factor.11 Such stabilization
leads to higher abundance of HIF-1a12 and subsequent
upregulation of HIF-1a-dependent genes. The P582 HIF-1a
T-allele carrier has been associated with more aggressive
forms of cancer, inlcuding renal cell carcinoma,13 breast
cancer,14 prostate cancer,11 and non-small cell lung cancer.15
However, nononcological clinical studies examining the
influence of this polymorphism have yielded conflicting
results with the HIF-1a T-allele being associated with a
higher prevalence of type-2 diabetes mellitus,12 and less
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Figure 3 | Restrictive cubic spline depicting the unadjusted
relationship (with 95% confidence bands) of (a) plasma vascular
endothelial growth factor-A (VEGF-A) (P¼ 0.39) and (b) plasma
angiopoietin-2 (Ang-2) (Po0.0001) with predicted probability of
dialysis requirement or in-hospital death.
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collateral vessel formation among patients with coronary
artery disease.16
In this study, the potential mechanisms underlying the
association of the HIF-1a T-allele with higher requirement
for organ support are unknown. Our data seemingly
contradict experimental observations that hypoxic precondi-
tioning and subsequent HIF-1a activation protect against
ischemic and nephrotoxic renal injury,17,18 and that the
extent of HIF-1a induction inversely correlates with tissue
injury.19 However, targeted deletion of HIF-1a has also been
shown to be protective against sepsis,20 which would support
the potential aggravating effect of the HIF-1a stabilizing
genetic variant observed in our study. In this regard, a
recently described new activator of prolyl-hydroxylase 2 that
is capable of rapidly degrading HIF-1a,21 might be a potential
therapeutic agent in states of excessive HIF-1a activation and
might be of clinical interest in AKI. It is also difficult to
translate experimental results to human AKI. We propose
that the poor outcomes observed among carriers of the
stabilizing HIF-1a T-allele might be due, in part, to the
slower degradation of the mutated HIF-1a after reversal of
tissue hypoxia, that is, when oxygen supply is restored,
thereby creating an effective state of ‘hypoxia extension.’ This
hypothesized maladaptive response of HIF-1a might be
conducive in part to an aberrant cytokine activation pattern
that has been described earlier in sepsis, and linked to HIF-1a
activation.22,23
With more than 60 HIF-1a target genes identified to date,
and their involvement in a multitude of biological processes
relevant to kidney function, including glucose and energy
metabolism, angiogenesis, cell migration, cell–cell and
cell–matrix interaction, proliferation, and apoptosis,3,24 there
are numerous potential downstream effectors of HIF-1a that
might contribute to the poor outcomes observed in our
study. We chose to examine two intermediate HIF-1a
phenotypes, VEGF-A and Ang-2. VEGF-A represents one of
the well-described HIF-1a target genes.25 Although we were
able to demonstrate a genotype–phenotype association
between HIF-1a and plasma VEGF-A, higher plasma
VEGF-A levels were associated with improved survival. The
need for dialysis and assisted mechanical ventilation are
clinical end points that are potentially associated with
vascular leakage phenomena. Although VEGF-A is a well-
established vascular permeability factor,26 we failed to
establish an association between this intermediate HIF-1a
phenotype and organ support. We can only speculate as to
whether circulating VEGF-A levels among patients with AKI
are not sufficiently high to cause vascular leakage as observed
in vitro,27 or whether a balance exists between different
effectors with opposing effects on vascular leakage.
Although there was a lack of association between HIF-1a
genotypes and plasma Ang-2 levels, this intermediate marker
was associated with the same adverse outcomes predicted by
the HIF-1a T-allele. The mechanism of Ang-2 regulation by
Table 4 | Association of plasma VEGF-A and Ang-2 levels with adverse clinical outcomes in patients with AKI
Outcome variable
Plasma VEGF-A level
(per 5-unit increase) P-value C statistic
Plasma Ang-2 level
(per 1-log-unit increase) P-value C statistic
In-hospital death
Unadjusted 0.90 (0.84, 0.96) 0.003 0.649 3.28 (2.14, 5.04) o0.0001 0.768
Adjusted for sex, race, and
APACHE II score
0.92 (0.86, 0.99) 0.02 0.843 2.37 (1.48, 3.78) 0.0003 0.844
Adjusted for sex, race, APACHE
II score, and HIF-1a genotype
0.92 (0.86, 0.98) 0.01 0.851 2.35 (1.46, 3.78) 0.0004 0.847
Dialysis requirement or in-hospital death
Unadjusted 1.00 (0.98, 1.02) 0.94 0.500 2.34 (1.65, 3.33) o0.0001 0.696
Adjusted for sex, race, and
APACHE II score
1.02 (0.99, 1.04) 0.19 0.776 1.68 (1.14, 2.48) 0.009 0.785
Adjusted for sex, race, APACHE
II score, and HIF-1a genotype
1.01 (0.98, 1.03) 0.49 0.806 1.61 (1.08, 2.39) 0.02 0.814
Assisted mechanical ventilation or dialysis requirement
Unadjusted 1.00 (0.98, 1.02) 0.99 0.504 2.12 (1.51, 2.80) o0.0001 0.678
Adjusted for sex, race, and
APACHE II score
1.02 (0.99, 1.04) 0.24 0.810 1.36 (0.92, 2.02) 0.13 0.806
Adjusted for sex, race, APACHE
II score, and HIF-1a genotype
1.01 (0.98, 1.03) 0.57 0.833 1.29 (0.87, 1.93) 0.21 0.833
Assisted mechanical ventilation, dialysis requirement or in-hospital death
Unadjusted 1.00 (0.98, 1.02) 0.72 0.553 2.27 (1.60, 3.23) o0.0001 0.691
Adjusted for sex, race, and
APACHE II score
1.01 (0.99, 1.03) 0.43 0.803 1.50 (1.01, 2.24) 0.04 0.806
Adjusted for sex, race,
APACHE II score, and
HIF-1a genotype
1.00 (0.98, 1.03) 0.98 0.839 1.42 (0.94, 2.13) 0.09 0.842
AKI, acute kidney injury; Ang-2, angiopoietin-2; 95% CI, 95% confidence interval for the odds ratio (OR); HIF-1a, hypoxia-inducible factor-1a; VEGF-A, vascular endothelial
growth factor A.
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HIF-1a is not as well established as that of VEGF-A,28,29 and
its induction tends to be cell-type specific.28,30 Ang-2 levels
are elevated in critically ill patients with sepsis7,31 and severe
trauma,32 and correlate with disease severity.31 Furthermore,
among septic patients with acute lung injury, Ang-2 levels
correlate with impaired pulmonary gas exchange7 and predict
acute lung injury.33 In our study, higher plasma Ang-2 levels
were associated with higher probability of mechanical
ventilation or dialysis requirement, and dialysis requirement
or in-hospital death. Thus, Ang-2 appeared to be a suitable
downstream effector of HIF-1a, and the inability to
demonstrate a genotype–phenotype association might be
due to our limited sample size. Nonetheless, further studies
to identify candidate downstream mediators of HIF-1a are
required. The fact that HIF-1a T-allele carrier state remained
independently associated with the composite end point of
dialysis requirement or in-hospital death even after adjust-
ment for Ang-2 level is in support of other more important
downstream HIF-1a gene effectors.
To our knowledge, this is the first study testing the
hypothesis of whether a functionally relevant polymorphism
of the HIF-1a gene is associated with adverse clinical
outcomes in patients with AKI. The heterogeneity of our
cohort was offset by the selective inclusion of patients with
more severe AKI requiring formal consultation of the
nephrology service. Although sizeable for a hospital-based
study, our cohort was relatively small for genetic epidemio-
logical studies. Our population was 90% white, reducing the
potential impact of race and ethnicity on genotype
prevalence. Of note, we found no ethnic differences among
genotype groups, but when the analyses were confined to
white subjects, the point estimates were not significantly
altered (data not shown). The use of baseline covariates such
as the APACHE II or MOF score, which incorporate several
demographic, physiological, and laboratory variables that are
individually associated with the composite end points,
strengthens our results. Our composite end points were also
chosen to account for survival bias when dialysis requirement
and assisted mechanical ventilation are being assessed as
outcome measures. The demonstrable genotype–phenotype
associations lend some additional credibility to the observed
association between the HIF-1a T-allele and the various
composite end points. Finally, there is a possibility that the
HIF-1a candidate gene polymorphism we studied might be
in linkage disequilibrium with other unidentified pathogenic
genetic variants.
In summary, this study supports the hypothesis that
HIF-1a gene polymorphism predicts adverse outcomes in
hospitalized patients with AKI. Larger studies are needed
to confirm these genetic associations and identify the
candidate downstream effectors of HIF-1a. These observa-
tions bolster previous knowledge that cytokine and
oxidative-stress gene polymorphisms play an important role
in the regulation of host inflammatory responses, and
contribute to altered morbidity and mortality among
patients with AKI.4,5
MATERIALS AND METHODS
Study design and participants
This was a prospective cohort study of hospitalized patients with
AKI, which was conducted between November 2003 and January
2008 at two tertiary care hospitals located in Boston, Massachusetts,
USA. All consecutive hospitalized adult patients with AKI, in whom
nephrology consultation was requested, were eligible for enrollment.
AKI was defined as a rise in serum creatinine of 0.5, 1.0, or 1.5 mg
per 100 ml from a baseline level of p1.9, 2.0–4.9, or X5.0 mg per
100 ml, respectively.34 The adopted definition preceded the AKI
network’s recently developed criteria.35
Exclusion criteria were as follows: age o18 years, pregnancy,
long-term dialysis, organ transplantation within the prior year, and
presence of acute obstructive uropathy. Written informed consent
was obtained from all participants or next of kin. The institutional
review board of each participating center approved the study
protocol.
Data collection
Medical records were reviewed prospectively to retrieve hospitaliza-
tion data, including baseline demographic characteristics, coexisting
conditions, and renal variables. At enrollment, oliguria was defined
by 24-h urine output o400 ml. Advanced chronic kidney disease
was assessed on the basis of a pre-morbid estimated glomerular
filtration rate o30 ml/min per 1.73 m2, as calculated by the
Modification of Diet in Renal Disease (MDRD) study equation.36
At enrollment, the presence of sepsis was ascertained using the
systemic inflammatory response syndrome (SIRS) criteria,37 and
two severity-of-illness scores were calculated, the Acute Physiology
and Chronic Health Evaluation (APACHE) II score38 and the MOF
score.39
Blood sampling and DNA extraction
At enrollment, EDTA-anticoagulated whole blood was collected.
Plasma was separated, and the remaining blood was aliquoted and
stored at 801C for subsequent DNA extraction. Genomic DNA was
extracted using a spin column method according to the manufac-
turer’s instructions (Qiagen Inc., Valencia, CA, USA). Final DNA
concentration was set at 50–200 ng/ml, and was determined by mini-
gel electrophoresis.
HIF-1a genotyping analyses
Genotyping of the HIF-1a gene in the coding region (exon 12,
position þ 85, C to T substitution) was performed with the allele-
specific primers TTCCTTCGATCAGTTGTCAC (þ 85C) and
TTCCTTCGATCAGTTGTCAT (þ 85T), and the consensus primer
TGAGGCTGTCCGACTTTGAG, which produces a PCR product of
280 bp. Perfectly matched primer pairs resulted in amplification of
target sequences, whereas mismatched primer pairs did not. In each
reaction, a second set of primers for exon 3 of the HLA-DRBI gene
was used as a control for PCR efficiency. The PCR amplification
reactions were carried out at 951C for 3 min, followed by 5 cycles at
951C for 30 s, 661C for 50 s, and 721C for 50 s. This was followed by
16 cycles with gradual decline of the annealing temperature by 11C
per cycle from 65 to 501C; 10 cycles at 951C for 30 s, 551C for 50 s,
and 721C for 50 s; and a final cycle at 721C for 5 min.
Measurement of plasma VEGF-A and Ang-2
Plasma VEGF-A and Ang-2 were measured by sandwich ELISA
using the commercially available kits (Quantikine VEGF
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Immunoassay, and Quantikine Angiopoietin-2 Immunoassay, R&D,
Minneapolis, MN, USA). Two measurements were performed per
sample, and outliers, as defined by values two standard deviations
below or above the mean, were re-measured. For VEGF-A, the
average inter- and intra-assay coefficient of variation was 7.3 and
5.4%, respectively, and for Ang-2, 9.0 and 5.9%, respectively. The
VEGF-A and Ang-2 results are expressed in pg/ml and are adjusted
for the white blood cell and platelet counts, as these molecules are
expressed, stored, and secreted by these circulating blood cells.40–42
Outcome measures
The primary end point of our study was the composite of dialysis
requirement or in-hospital death. Secondary outcome measures
were severity of organ dysfunction, as measured by the MOF score,
organ support, as defined by need for assisted mechanical
ventilation or dialysis requirement, in-hospital death and the
composite of dialysis requirement, assisted mechanical ventilation
or in-hospital death. The composite end points of organ support or
in-hospital death were chosen as they take into consideration
survival bias for dialysis requirement or assisted mechanical
ventilation.
Statistical analyses
The genotype frequencies were tested for Hardy–Weinberg equili-
brium using a standard w2-test. Comparisons between genotype
groups were made by the Kruskall–Wallis test or the two-tailed
Mann–Whitney test for continuous variables, and by w2-test or
Fisher’s exact test for categorical variables. Results are expressed as
means (with standard deviation) or percentages.
A general linear model was used to estimate the mean plasma
VEGF-A and Ang-2 levels in each genotype category, adjusting for
white blood cell and platelet counts. For this analysis, the results are
displayed as means±s.e. A proportional odds model was used to
examine the association of the HIF-1a T-allele carrier, plasma
VEGF-A and Ang-2 level with the MOF score.
Logistic regression analyses were used to examine the association
of the HIF-1a CT/TT genotypes or T-allele carrier (vs CC genotype)
with the afore-mentioned outcomes, using a recessive genetic model.
All models were adjusted for sex, race, and APACHE II score. We
performed similar analyses using an additive genetic model (i.e.,
copies of the HIF-1a minor allele). In a sensitivity analysis, other
covariates were used including sex, race, age, and either sepsis or the
MOF score. The results of the logistic regression analyses are
displayed as odds ratios with 95% CI.
The functional form of plasma VEGF-A and Ang-2 level with
dialysis requirement or in-hospital death was examined and
graphically displayed using restricted cubic spline functions with
four knots.43 Plots of the restricted splines were constructed using
the Design library of the R package.44
Logistic regression analyses were also used to examine the
association of plasma VEGF-A and Ang-2 levels, our two
hypothesized downstream effectors of HIF-1a, with similar clinical
end points. For these analyses, the Ang-2 variable was log
transformed due to a skewed distribution. Models were adjusted
for sex, race, APACHE II score, and HIF-1a genotypes. We also
formally tested for interactions between HIF-1a genotypes and
either VEGF-A or Ang-2 for the outcomes of interest.
All statistical analyses were performed using the SAS software
(SAS Institute, Cary, NC, USA) version 9.1. All P-values are two-
sided, and a P-value of less than 0.05 was considered significant.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We are indebted to the patients and their next of kin for participating
in this study. This study was supported by grants from the National
Institutes of Health (DK065102 and DK077751, to B.L.J.). O.L. was
supported by a grant from the American Heart Association. We thank
Robert W. MacKinnon, RN, for assistance with enrollment of study
participants.
REFERENCES
1. Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality,
length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005;
16: 3365–3370.
2. Liangos O, Wald R, O’Bell J et al. Epidemiology and outcomes of acute
renal failure in hospitalized patients: a national survey. Clin J Am Soc
Nephrol 2006; 1: 43–51.
3. Haase VH. Hypoxia-inducible factors in the kidney. Am J Physiol Renal
Physiol 2006; 291: F271–F281.
4. Jaber B, Rao M, Guo D et al. Cytokine promoter gene polymorphisms and
mortality in acute renal failure. Cytokine 2004; 25: 212–219.
5. Perianayagam MC, Liangos O, Kolyada AY et al. NADPH oxidase p22phox
and catalase gene variants are associated with biomarkers of oxidative
stress and adverse outcomes in acute renal failure. J Am Soc Nephrol
2007; 18: 255–263.
6. Tanimoto K, Yoshiga K, Eguchi H et al. Hypoxia-inducible factor-1alpha
polymorphisms associated with enhanced transactivation
capacity, implying clinical significance. Carcinogenesis 2003; 24:
1779–1783.
7. Parikh SM, Mammoto T, Schultz A et al. Excess circulating angiopoietin-2
may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med
2006; 3: e46.
8. Shapiro NI, Yano K, Okada H et al. A prospective, observational study of
soluble FLT-1 and vascular endothelial growth factor in sepsis. Shock
2008; 29: 452–457.
9. Semenza GL. HIF-1: mediator of physiological and pathophysiological
responses to hypoxia. J Appl Physiol 2000; 88: 1474–1480.
10. Clifford SC, Astuti D, Hooper L et al. The pVHL-associated SCF ubiquitin
ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and
HIF-1alpha in renal cell carcinoma. Oncogene 2001; 20: 5067–5074.
11. Fu XS, Choi E, Bubley GJ et al. Identification of hypoxia-inducible factor-
1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that
prevents normoxia-induced degradation. Prostate 2005; 63: 215–221.
12. Yamada N, Horikawa Y, Oda N et al. Genetic variation in the hypoxia-
inducible factor-1alpha gene is associated with type 2 diabetes in
Japanese. J Clin Endocrinol Metab 2005; 90: 5841–5847.
13. Ollerenshaw M, Page T, Hammonds J et al. Polymorphisms in the hypoxia
inducible factor-1alpha gene (HIF1A) are associated with the renal cell
carcinoma phenotype. Cancer Genet Cytogenet 2004; 153: 122–126.
14. Lee JY, Choi JY, Lee KM et al. Rare variant of hypoxia-inducible factor-
1alpha (HIF-1A) and breast cancer risk in Korean women. Clin Chim Acta
2008; 389: 167–170.
15. Koukourakis MI, Papazoglou D, Giatromanolaki A et al. C2028T
polymorphism in exon 12 and dinucleotide repeat polymorphism in
intron 13 of the HIF-1alpha gene define HIF-1alpha protein expression in
non-small cell lung cancer. Lung Cancer 2006; 53: 257–262.
16. Resar JR, Roguin A, Voner J et al. Hypoxia-inducible factor 1alpha
polymorphism and coronary collaterals in patients with ischemic heart
disease. Chest 2005; 128: 787–791.
17. Matsumoto M, Makino Y, Tanaka T et al. Induction of renoprotective gene
expression by cobalt ameliorates ischemic injury of the kidney in rats.
J Am Soc Nephrol 2003; 14: 1825–1832.
18. Weidemann A, Bernhardt WM, Klanke B et al. HIF activation protects from
acute kidney injury. J Am Soc Nephrol 2008; 19: 486–494.
19. Rosenberger C, Heyman SN, Rosen S et al. Up-regulation of HIF in
experimental acute renal failure: evidence for a protective transcriptional
response to hypoxia. Kidney Int 2005; 67: 531–542.
20. Peyssonnaux C, Cejudo-Martin P, Doedens A et al. Cutting edge:
Essential role of hypoxia inducible factor-1alpha in development of
lipopolysaccharide-induced sepsis. J Immunol 2007; 178: 7516–7519.
21. Choi HJ, Song BJ, Gong YD et al. Rapid degradation of hypoxia-inducible
factor-1alpha by KRH102053, a new activator of prolyl hydroxylase 2.
Br J Pharmacol 2008; 154: 114–125.
1328 Kidney International (2009) 75, 1322–1329
o r i g i n a l a r t i c l e AY Kolyada et al.: HIF-1a gene polymorphism in acute kidney injury
22. Blouin CC, Page EL, Soucy GM et al. Hypoxic gene activation by
lipopolysaccharide in macrophages: implication of hypoxia-inducible
factor 1alpha. Blood 2004; 103: 1124–1130.
23. Frede S, Stockmann C, Freitag P et al. Bacterial lipopolysaccharide induces
HIF-1 activation in human monocytes via p44/42 MAPK and NF-kappaB.
Biochem J 2006; 396: 517–527.
24. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem
Pharmacol 2002; 64: 993–998.
25. Forsythe JA, Jiang BH, Iyer NV et al. Activation of vascular endothelial
growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell
Biol 1996; 16: 4604–4613.
26. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular
permeability factor that promotes accumulation of ascites fluid. Science
1983; 219: 983–985.
27. Chandra A, Barillas S, Suliman A et al. A novel fluorescence-based
cellular permeability assay. J Biochem Biophys Methods 2007; 70:
329–333.
28. Kelly BD, Hackett SF, Hirota K et al. Cell type-specific regulation of
angiogenic growth factor gene expression and induction of angiogenesis
in nonischemic tissue by a constitutively active form of hypoxia-inducible
factor 1. Circ Res 2003; 93: 1074–1081.
29. Fong GH. Mechanisms of adaptive angiogenesis to tissue hypoxia.
Angiogenesis 2008; 11: 121–140.
30. Yamakawa M, Liu LX, Date T et al. Hypoxia-inducible factor-1 mediates
activation of cultured vascular endothelial cells by inducing multiple
angiogenic factors. Circ Res 2003; 93: 664–673.
31. Orfanos SE, Kotanidou A, Glynos C et al. Angiopoietin-2 is increased in
severe sepsis: correlation with inflammatory mediators. Crit Care Med
2007; 35: 199–206.
32. Ganter MT, Cohen MJ, Brohi K et al. Angiopoietin-2, marker and mediator
of endothelial activation with prognostic significance early after trauma?
Ann Surg 2008; 247: 320–326.
33. van der Heijden M, van Nieuw Amerongen GP, Koolwijk P et al.
Angiopoietin-2, permeability oedema, occurrence and severity of
ALI/ARDS in septic and non-septic critically ill patients. Thorax 2008.
34. Hou SH, Bushinsky DA, Wish JB et al. Hospital-acquired renal insufficiency:
a prospective study. Am J Med 1983; 74: 243–248.
35. Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network (AKIN):
report of an initiative to improve outcomes in acute kidney injury. Crit
Care 2007; 11: R31.
36. K/DOQI NKF. Clinical Practice Guidelines for Chronic Kidney Disease:
Evaluation, Classification and Stratification. Am J Kidney Dis 2002;
39(Suppl 1): S1–S266.
37. Levy MM, Fink MP, Marshall JC et al. 2001 SCCM/ESICM/ACCP/ATS/SIS
International Sepsis Definitions Conference. Crit Care Med 2003; 31:
1250–1256.
38. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease
classification system. Crit Care Med 1985; 13: 818–829.
39. Knaus WA, Wagner DP. Multiple systems organ failure: epidemiology and
prognosis. Crit Care Clin 1989; 5: 221–232.
40. Ito A, Hirota S, Mizuno H et al. Expression of vascular permeability factor
(VPF/VEGF) messenger RNA by plasma cells: possible involvement in the
development of edema in chronic inflammation. Pathol Int 1995; 45:
715–720.
41. Maloney JP, Silliman CC, Ambruso DR et al. In vitro release of vascular
endothelial growth factor during platelet aggregation. Am J Physiol 1998;
275(3 Part 2): H1054–H1061.
42. Frechette JP, Martineau I, Gagnon G. Platelet-rich plasmas: growth factor
content and roles in wound healing. J Dent Res 2005; 84: 434–439.
43. Stone C, Koo CY. Additive splines in statistics. In: Proceedings of the Statistical
Computing Section of the American Statistical Association 1995: 45–48.
44. R: A language and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria. 2005. (Accessed at http://
www.R-project.org).
Kidney International (2009) 75, 1322–1329 1329
AY Kolyada et al.: HIF-1a gene polymorphism in acute kidney injury o r i g i n a l a r t i c l e
